Navigation Links
Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
Date:6/3/2008

SAN FRANCISCO, June 3 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Investigational New Drug (IND) application for its lead compound, MitoQ(R). With the IND acceptance, the Company will involve U.S. clinical centers in the development of MitoQ for the treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD).

"We look forward to working with FDA to further explore MitoQ's potential by conducting further trials in the United States," said Ken Taylor, Ph.D., Chief Executive Officer of Antipodean Pharmaceuticals. "The Company is actively seeking a pharmaceutical partner with whom to work to achieve this goal."

In April 2008, the Company announced positive results of a clinical study of MitoQ in patients with Hepatitis C virus (HCV) who had failed standard antiviral treatment. The data from this Phase 2 trial were presented at the European Association for the Study of Liver (EASL) conference. Results showed a significant reduction in elevated alanine aminotransferase (ALT) levels as compared to placebo. The ALT decrease from baseline was 26.4% (p<0.002) for patients in the 40mg dose group. This suggests that MitoQ can reduce necroinflammation and may halt disease progression to fibrosis or cirrhosis. The drug was well tolerated, with no significant safety issues.

About MitoQ(R)

MitoQ is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative damage and prevents liver cell apoptosis. MitoQ is based on a novel technology, targeted lipophilic cations that transport and concentrate antioxidants into the mitochondria-organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. MitoQ can reduce the hepatic oxidative damage that is induced by viral infection and that is also involved in the progression of Non-alcoholic Fatty Liver Disease (NA
'/>"/>

SOURCE Antipodean Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
2. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
3. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
6. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
8. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
9. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... guide titled, “Is Group Therapy Right for Me?” The ... joining group therapy or counseling, in addition to common ... in group therapy improve not only from the interventions ... the group and receiving feedback from group members,” says ...
(Date:9/2/2014)... 2014 Friendship Village of Schaumburg ... “This creates a contemporary marketing presence and visually ... parent organization, Friendship Senior Options,” said Stephen A. ... “By changing the logo, we are making sure ... seniors and their families.” , Friendship Village is ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
(Date:9/2/2014)... WASHINGTON Patients who return to the emergency department within ... are anxious about their symptoms and have lost trust in ... results of a study published online today in Annals ... Department: The Patient Perspective" ). , "When asked ... reported feeling that their symptoms were too severe to wait ...
(Date:9/2/2014)... -- Two new studies further confirm the health benefits ... breast-fed have a lower risk of ear, throat and ... finds a similar trend when it comes to allergies. ... in the immediate newborn period," said Dr. Jennifer Wu, ... City. She was not involved in the new studies. ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... BALTIMORE, June 16 Lupin Pharmaceuticals, Inc. (LPI),announced ... the Company,s,Abbreviated New Drug Application (ANDA) for Escitalopram ... U.S. Food and Drug Administration (USFDA)., Lupin,s ... Laboratories, Lexapro(R) tablets, indicated for the treatment of,major ...
... Researchers at Ben-Gurion University of the Negev (BGU) in ... tested at a Washington, D.C. hospital, that enables doctors ... instead of touching a screen, keyboard or mouse which ... just released article. , The June article," A Gesture-based ...
... to injury-related deaths, the gap between black and white ... researchers at the Johns Hopkins Bloomberg School of Public ... injury-related deaths among blacks ages 15 to 24 decreased, ... published in the June, 2008, edition of Injury ...
... and PLM Based on Dassault Systemes, Newly,Introduced V6 Platform and ... ... ST. PAUL, Minnesota, June 16 Intercim LLC, a global,leader ... highly regulated industries and Dassault,Systemes (DS) (Nasdaq: DASTY; Euronext Paris: ...
... COLUMBIA, S.C., June 16 BlueCross BlueShield,of South ... of,the company,s health insurance plans that also adds ... options., "With increasing health care costs forcing ... dropping their insurance or not,picking it up to ...
... Coffee,s aroma kick-starts genes in the brain, Journal of ... a wake-up call to the brain? Or just smell its ... some of the first evidence that simply inhaling coffee aroma ... with laboratory rats, they found that coffee aroma orchestrates the ...
Cached Medicine News:Health News:Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets 2Health News:Gesture interface device developed by Ben-Gurion University of the Negev 2Health News:Racial disparities reduced in injury related mortality 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 3Health News:S.C. BlueCross Launches Less-Costly Plans Geared to Groups Seeking More Options 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 3Health News:American Chemical Society's Weekly PressPac: June 11, 2008 4Health News:American Chemical Society's Weekly PressPac: June 11, 2008 5Health News:American Chemical Society's Weekly PressPac: June 11, 2008 6Health News:American Chemical Society's Weekly PressPac: June 11, 2008 7Health News:American Chemical Society's Weekly PressPac: June 11, 2008 8
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... ALBANY, New York , September 2, 2014 ... market report published by Transparency Market Research "Latin ... and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility ... Telehealth and Telemedicine, Respiratory Therapy, Infusion Therapy and ... Share, Growth, Trends and Forecast, 2014 - 2020" ...
(Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11
... PediaVision today announced that Loma Linda University,s Vision ... of California to receive the revolutionary new vision ... of Ophthalmology is offering free vision screenings to ... of First 5 Riverside , which invests ...
... DURHAM, N.C., Sept. 29, 2011 CoLucid Pharmaceuticals, Inc., ... Chief Executive Officer, Thomas P. Mathers, will be making ... Conference at 9:35 – 10:00 a.m. on Tuesday, October ... Hotel in Tokyo, Japan. The partnering meeting is expected ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan 2
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: